Orbimed Advisors LLC, 10% Owner at Traws Pharma, Inc. (TRAW), bought 597,729 shares at $1.67 ($998K) on 2026-04-16, disclosed to the SEC on 2026-04-28.
Orbimed Advisors LLC executed the largest insider purchase in TRAW's history by buying nearly $1M of shares at $1.67, signaling confidence despite recent underperformance. This transaction coincides with a sharp 51.63% decline over the last 90 days, suggesting a potential contrarian entry point.
TRAW is currently trading at $1.19, a 51.63% decline over the last 90 days and 63.55% below its 52-week high of $3.265.
Catalysts include the Q4 2025 earnings call on 2026-04-16 which highlighted a 'financial turnaround,' and the hVIVO deal announced on 2026-04-14 for a flu human challenge trial. Additionally, a Zacks article on 2026-04-20 noted strong analyst agreement on earnings estimates.
Risks include a short interest of 4.5% and the recent sector update on 2026-05-08 indicating healthcare stocks are lower.
Something here stands out, but not much.
| Filing → |
| BRVE | BUY | 2026-08-11 | $34.9M | — | Filing → |
| SCTX | BUY | 2026-07-29 | $15.0M | — | Filing → |
| SION | SELL | 2026-07-09 | $3.9M | — | Filing → |